# Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

> **NCT06802315** · PHASE2 · RECRUITING · sponsor: **University of Illinois at Chicago** · enrollment: 38 (estimated)

## Conditions studied

- Acute Myeloid Leukemia, Relapsed, Adult
- Acute Myeloid Leukemia Refractory
- Chronic Myeloid Leukemia - Accelerated Phase
- Myelodysplastic Syndromes

## Interventions

- **RADIATION:** Intensity modulated total marrow irradiation
- **DRUG:** Cyclophosphamide (CTX)
- **DRUG:** Fludarabine (Fludara)
- **DRUG:** Busulfan (conditioning for ALLO Transplant)

## Key facts

- **NCT ID:** NCT06802315
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-04
- **Primary completion:** 2030-03
- **Final completion:** 2032-03
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06802315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06802315, "Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06802315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*